CTOs on the Move

Huyabio

www.huyabio.com

 
HUYABIO is the leader in accelerating the global development of novel biopharmaceutical product opportunities originating in China enabling faster, more cost-effective and lower-risk drug development in the global markets. Through extensive collaboration with biopharmaceutical, academic and commercial organizations, it has built the largest China-sourced compound portfolio covering all therapeutic areas. With offices in the US, Japan, South Korea, Canada, Ireland and eight strategic locations across China, the Company has become a partner of choice to accelerate product development and maximize value globally.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.huyabio.com
  • 12531 High Bluff Drive Suite 138
    San Diego, CA USA 92130
  • Phone: 858.798.8800

Executives

Name Title Contact Details

Similar Companies

Goodness Growth

Goodness Growth Holdings, Inc. is a cannabis company whose mission is to provide safe access, quality products and value to its customers while supporting its local communities through active participation and restorative justice programs. The Company is evolving with the industry and is in the midst of a transformation to being significantly more customer-centric across its operations, which include cultivation, manufacturing, wholesale and retail business lines. Today, the Company is licensed to grow, process, and/or distribute cannabis in four markets and operates 14 dispensaries in three states.

Xerimis Inc

Xerimis Inc is a Moorestown, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Next Generation Clinical Research Consulting

Next Generation Clinical Research Consulting is a Oregon, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ORIC Pharmaceuticals

ORIC was established in 2014 with a bold vision of Overcoming Resistance in Cancer. Resistance limits the efficacy of otherwise significant cancer treatment breakthroughs, regardless of modality. Our ambition at ORIC is to discover and develop innovative therapies that benefit patients with cancer, including by making existing therapies more effective for a longer period of time. Our initial project was a small molecule antagonist of the glucocorticoid receptor (GR), which has been implicated in resistance to various treatment modalities—including chemotherapy, immunotherapy, and anti-hormonal therapy—and across multiple cancers. The resulting product candidate, ORIC-101, is now being studied in clinical trials for a range of solid tumors. ORIC-101 and other pipeline programs are a result of rigorous, hands-on experimentation and medicinal chemistry efforts led by our internal team of scientists in biology, medicinal chemistry, DMPK and translational medicine, with assistance from academic collaborators and continued guidance from our founders and board members. This collective team maintains an unwavering focus on improving the lives of patients by tackling the problem of cancer treatment resistance.

Jeiven Pharmaceutical Consulting

Jeiven Pharmaceutical Consulting is a Scotch Plains, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.